Oral Arsenic Trioxide and Itraconazole for the Treatment of Patients With Advanced Basal Cell Carcinoma

Trial Profile

Oral Arsenic Trioxide and Itraconazole for the Treatment of Patients With Advanced Basal Cell Carcinoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Arsenic trioxide (Primary) ; Itraconazole (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Dec 2016 Planned End Date changed from 1 Feb 2018 to 1 Nov 2019.
    • 09 Dec 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top